Semax Research for Optic Nerve Disorders
An evidence-based overview of research examining Semax in the context of optic nerve disorders. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semax is approved in Russia for optic nerve atrophy and has demonstrated benefits in various optic neuropathies. Clinical trials show improved visual acuity, expanded visual fields, and enhanced optic nerve electrical sensitivity and conductivity.
Studies in patients with vascular, toxic-allergic, and inflammatory optic nerve diseases showed that Semax protected nervous tissue and stimulated recovery, particularly when treatment was initiated in the acute stage. Both intranasal drops and endonasal electrophoresis delivery methods showed efficacy.
In glaucomatous optic neuropathy, Semax-containing therapy demonstrated advantages over traditional treatment through both neuroprotective and neurotrophic mechanisms, as documented by electrophysiological and computer examination findings.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Optic Nerve Disorders
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semax may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.